Brentuximab Vedotin
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
- Brentuximab Vedotin
- Pharmacist Assessment Report
- Brentuximab Vedotin: From Hodgkin Lymphoma to Follicular Lymphoma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Brentuximab Vedotin: From Hodgkin Lymphoma to Follicular Lymphoma
One-Sentence Summary
Brentuximab vedotin is an anti-CD30 antibody-drug conjugate originally used to treat Hodgkin lymphoma. The TxGNN model predicts it may be effective for follicular lymphoma, but the supporting evidence is thin: 5 clinical trials (3 withdrawn or terminated, 1 recruiting, none with results) and 20 publications, most of which concern peripheral T-cell lymphoma rather than follicular lymphoma.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hodgkin lymphoma (classical Hodgkin lymphoma and related subtypes) |
| Predicted New Indication | Follicular lymphoma |
| TxGNN Prediction Score | 0.9989 |
| Evidence Level | L3 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold (treat as a research question) |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, brentuximab vedotin is an antibody-drug conjugate that binds CD30 on tumour cells and delivers the cytotoxic agent monomethyl auristatin E (MMAE). Its efficacy in CD30-positive Hodgkin lymphoma is established.
The mechanistic link to follicular lymphoma is weak. Follicular lymphoma is generally CD30-low or CD30-negative, so any benefit would likely be limited to CD30-positive subsets, transformed disease, or bystander effects of MMAE. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The retrieved literature mainly addresses peripheral T-cell lymphoma, not follicular lymphoma.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT04587687 | Phase 2 | Recruiting | 23 | Brentuximab vedotin plus bendamustine in relapsed/refractory follicular lymphoma; directly on-indication, results not yet available |
| NCT02594163 | Phase 2 | Terminated | 25 | Rituximab and bendamustine with or without brentuximab vedotin in relapsed/refractory CD30-positive DLBCL; randomised but underpowered |
| NCT01805037 | Phase 1/2 | Terminated | 20 | Brentuximab vedotin plus rituximab frontline in CD30-positive and/or EBV-positive lymphomas; not follicular-specific |
| NCT04138875 | Phase 2 | Withdrawn | 0 | Rituximab, brentuximab vedotin and bendamustine in post-transplant lymphoproliferative disorders; no data generated |
| NCT02623920 | Phase 2 | Withdrawn | 0 | Brentuximab vedotin with bendamustine and rituximab in CD30-positive relapsed/refractory B-cell NHL; no data generated |
| NCT04795869 | Phase 2 | Withdrawn | 0 | Brentuximab vedotin plus pembrolizumab in recurrent peripheral T-cell lymphoma; no data generated |
No ANZCTR identifiers were available in the data compiled for this report.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38364196 | 2024 | RCT | J Clin Oncol | Final analysis of Ro-CHOP (romidepsin plus CHOP) in untreated peripheral T-cell lymphoma; does not involve brentuximab vedotin or follicular lymphoma |
| 40758949 | 2025 | Cohort | Blood Adv | LYSA phase 2 study of brentuximab vedotin plus gemcitabine in relapsed/refractory CD30-positive peripheral T-cell lymphoma |
| 33320379 | 2021 | Cohort | Eur J Haematol | Brentuximab vedotin added to ICE in relapsed/refractory peripheral T-cell lymphoma |
| 35663281 | 2022 | Review | Leuk Res Rep | Immunotherapy in indolent non-Hodgkin lymphoma, including follicular lymphoma |
| 38306597 | 2024 | Review | Blood | Current and upcoming treatment of common peripheral T-cell lymphoma subtypes, including brentuximab vedotin-based regimens |
| 39644004 | 2024 | Review | Hematology ASH Educ Program | Incorporating brentuximab vedotin and novel agents into peripheral T-cell lymphoma management |
| 32476657 | 2020 | Case report | Gulf J Oncol | Grade I follicular lymphoma transformed to CD30-positive anaplastic large cell lymphoma, with complete response to brentuximab vedotin and high-dose methotrexate |
| 41409526 | 2025 | Case report | Skin Appendage Disord | Extensive alopecia mucinosa (follicular mucinosis) responding to brentuximab vedotin; unrelated to follicular lymphoma |
Note that none of these publications reports brentuximab vedotin outcomes in follicular lymphoma proper. The single relevant signal is one case report of a transformed lymphoma.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10166C | Adcetris | Powder for I.V. infusion 50 mg | Not stated in the data compiled for this report |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (CD30-directed antibody-drug conjugate with an MMAE cytotoxic payload) |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the PI; at minimum, full blood count with differential and liver function |
| Handling Protection | Follow local cytotoxic drug handling requirements |
Safety Considerations
Drug Interactions: The interaction screen returned 100 interactions, all graded Moderate in the DDInter source. The entries listed are mainly antidiabetic agents (for example acarbose, metformin, pioglitazone, glimepiride, glipizide, and the SGLT2 inhibitors canagliflozin, dapagliflozin, empagliflozin and ertugliflozin, plus the GLP-1 agonists albiglutide, dulaglutide and exenatide). Other listed agents include bupropion, clarithromycin, clotrimazole, chenodeoxycholic acid and eliglustat. The clinical significance of these entries should be checked against the PI and an interaction reference.
For warnings and contraindications, please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Follicular lymphoma is rarely CD30-positive, so the mechanistic link is weak. The only on-indication trial (NCT04587687) is a small, recruiting Phase 2 study without results, and the other follicular-relevant trials were withdrawn or terminated. The evidence level is L3 and the stage is a research question, not a candidate for repurposing action.
To proceed, the following is needed:
- Results from NCT04587687, plus data on CD30 expression in follicular lymphoma to identify any responsive subgroup
- Mechanism of action data (currently missing)
- TGA Product Information warnings, contraindications and approved indication text (currently missing, and a blocking gap for safety screening)
- Follicular-specific efficacy and safety data for brentuximab vedotin with or without bendamustine
Other predicted indications of note: B-cell neoplasm (particularly CD30-positive DLBCL) has the strongest evidence in the data compiled for this report (Evidence Level L2, including a completed 176-patient Phase 2 trial and an ongoing Phase 3 trial, NCT04404283). It would be a better-supported candidate for further evaluation under “Proceed with Guardrails”, although evidence there is concentrated in CD30-positive disease and no B-cell-specific Phase 3 efficacy result has been identified.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.